The reaffirmation of the Outperform rating and the increase in price target by a reputable analyst like Ritu Baral suggests a strong confidence in Madrigal Pharmaceuticals' future performance. This positive outlook is likely to influence investor sentiment positively in the short term, potentially leading to an increase in the stock price.